Core Insights - PainReform Ltd. has announced advancements in its solar energy business unit, DeepSolar, focusing on the development of an automated reporting engine that enhances solar asset performance analysis and communication [1][3]. Company Overview - PainReform Ltd. operates in two main sectors: reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform [5]. - DeepSolar specializes in advanced digital asset management technologies for utility-scale solar plants, utilizing AI algorithms to convert complex operational data into actionable insights [4][5]. Product Development - The new AI-powered reporting engine aims to automate the process of generating performance reports, which currently requires manual data aggregation from various systems [2][3]. - This engine will consolidate and interpret data from multiple sources, providing customized reports in minutes, tailored to user-defined analysis depth, visualization style, and reporting frequency [3]. Strategic Vision - The automated reporting system is seen as a significant step towards making DeepSolar's AI capabilities more practical and accessible, facilitating a quicker transition from analysis to actionable insights [4].

TEL AVIV, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics, was recently featured in a Watchlist Interview produced in collaboration with The Market Link, highlighting its participation in the NVIDIA Connect program. The interview features key elements of DeepSolar Predict that are attracting interest from potential partners and customers, reflecting the growing demand ...

U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F - 2 | | Condensed Statements of Comprehensive Loss | F - 3 | | Condensed Statements of Changes in Shareholders' Equity | F - 4 | | Condensed Statements of Cash Flows | F - 5 | | Notes to Condensed Financial Statements | F - 6 - F - 15 | PAINREFORM LTD. CONDENSED BALANCE SHEETS (Unaudited) U.S. dollars in thousands | | | As of | | | ...

Core Insights - PainReform Ltd. has made significant advancements in both specialty pharmaceuticals and renewable energy technologies during the first half of 2025, focusing on non-opioid solutions for pain management and AI-driven solar analytics [3][12] Pharmaceutical Programs - The company acquired a majority interest in LayerBio, enhancing its pipeline with the OcuRing™-K platform, a novel therapy targeting a global market of approximately $9 billion for post-surgical pain management [6][7] - Continued development of PRF-110 is underway, which showed significant efficacy in the early postoperative period despite not meeting primary endpoints in a Phase 3 trial [7] DeepSolar Division - The DeepSolar division has shown strong momentum, highlighted by the completion of the MyDeepSolar consumer app and acceptance into NVIDIA's Connect Program, which will aid in developing the DeepSolar Predict forecasting solution [3][14] - A successful 92MW pilot project with Econergy in Romania has transitioned into the company's first commercial customer agreement, marking a significant step in commercial deployment [3][14] Financial Performance - The company reduced its net loss to approximately $2.3 million for the six months ended June 30, 2025, down from $12.8 million in the same period the previous year [11] - Research and development expenses significantly decreased to approximately $0.3 million compared to $11.4 million in the prior year, primarily due to the completion of the Phase 3 clinical trial for PRF-110 [9] - As of June 30, 2025, PainReform maintained cash and cash equivalents of approximately $3.5 million and positive working capital of approximately $1.5 million [11]

Core Insights - Shares of PainReform surged nearly 130% after its renewable energy arm, DeepSolar, was accepted into the Nvidia Connect Program, trading at $3.06, although the stock is still down over 20% year-to-date [1] Group 1: Nvidia Partnership and Technology - Through the Nvidia program, DeepSolar will access advanced AI frameworks and tools to enhance its solar forecasting solution, DeepSolar Predict, which aims to improve weather forecast accuracy by up to 50% [2] - The integration of NVIDIA's AI capabilities with DeepSolar's expertise is expected to redefine photovoltaic energy forecasting and optimization [3] Group 2: Financial Performance and Challenges - Despite the recent stock surge, PainReform shares have lost over 80% in the past year, indicating ongoing struggles for the company [4] - The company is diversifying into biotechnology with a majority stake acquisition in LayerBio, which supports the development of OcuRing-K, a drug delivery system for post-surgical pain management [4][5] - The investment in OcuRing-K could total $3 million, with $600,000 already committed [5]

Core Insights - DeepSolar, a solar energy business unit of PainReform Ltd., has been accepted into the NVIDIA Connect Program, which provides access to advanced AI tools and support for developing its solar forecasting platform [1][2][6] - The DeepSolar Predict solution aims to enhance weather prediction accuracy by up to 50%, improving the reliability of solar energy output predictions [2][3] - The software platform has already shown the ability to increase energy production and reduce operational and maintenance costs by up to 30% [4] Company Developments - Participation in the NVIDIA Connect Program allows DeepSolar to leverage NVIDIA's AI frameworks and engineering support, which will aid in the development of its solar forecasting solution [2][6] - Initial engagements with photovoltaic (PV) developers and utility-scale operators are underway to test DeepSolar Predict in real-world scenarios [4] - The advancements in solar forecasting align with growing demands for intelligent asset management solutions in the solar industry, particularly as alternative energy needs increase [3][5] Industry Context - The need for accurate weather forecasting is critical for solar asset owners to balance supply predictions with market conditions [3] - Enhanced predictive capabilities from DeepSolar Predict are expected to provide advantages such as reducing imbalance penalties from inaccurate forecasts and maximizing revenue through improved energy sale timing [8] - The global solar industry is experiencing accelerated deployment, necessitating performance optimization and cost control solutions [3][5]

Core Insights - PainReform Ltd. has acquired a majority equity interest in LayerBio, a biotechnology company focused on sustained-release drug delivery technologies in ophthalmology, particularly targeting the cataract surgery market [1][2][8] - The global cataract surgery market is valued at over $3 billion in the U.S., with an estimated 4.5 million surgeries performed annually, driven by an aging population and improved surgical access [2][3] - LayerBio's lead product, OcuRing™-K, is a sustained-release intraocular ring designed to deliver Ketoralac, addressing the need for "dropless" postoperative solutions in cataract surgery [4][5] Company Overview - PainReform focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies, with a commitment to applying precision technology in healthcare and sustainable energy [9] - LayerBio's technology allows for extended drug release from a single application, minimizing the need for patient-administered drops and maximizing local therapeutic effects [6] - Dr. Ken Mandell, a recognized leader in sustained-release drug delivery, will continue to lead LayerBio, guiding its operations and product development efforts [7] Market Opportunity - The acquisition positions PainReform to address a significant clinical need in the cataract surgery market, with plans to advance OcuRing™-K through clinical development in the U.S. [8] - The companies aim to explore broader ophthalmic applications beyond cataract surgery, including glaucoma and corneal transplants [8] - OcuRing™-K offers a transformative alternative to traditional postoperative regimens, which often involve complex eye drop schedules that can lead to poor patient compliance [3][5]

Core Insights - PainReform Ltd. has signed a strategic investment agreement with LayerBio Inc. to expand into the ophthalmology market, targeting the high-volume cataract surgery segment with a new drug delivery platform [1][2][5] - LayerBio's lead product, OcuRing™-K, is a sustained-release intraocular ring designed to deliver anti-inflammatory and analgesic agents post-cataract surgery, potentially replacing traditional eye drops [3][4] - The investment agreement includes an initial investment of $600,000, with a total commitment of $3 million contingent on achieving specific milestones [4][5] Company Overview - PainReform focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform [7][8] - The company aims to provide prolonged post-surgical pain relief while minimizing opioid reliance through its proprietary extended-release drug-delivery system [8] Market Opportunity - Approximately 3 million cataract surgeries are performed annually in the United States, presenting a significant clinical and commercial opportunity for OcuRing-K [3] - The strategic investment aligns with PainReform's mission to broaden its non-opiate pain management pipeline in high-need surgical markets [5][6] Leadership and Management - Dr. Ken Mandell, a recognized leader in sustained-release drug delivery and founder of LayerBio, will continue to lead the company [5][6] - Dr. Mandell has a strong background in ophthalmology and biotechnology, holding over 15 U.S. patents and contributing to numerous clinical trials [5]

Group 1 - Blade Ranger Ltd. achieved a first milestone in the sale of its DeepSolar operations to PainReform, resulting in the maturation of zero-exercise-price warrants [1][2] - The agreement completed in March 2025 included common shares of PainReform representing approximately 9.9% of the company's equity and about 3.08 million warrants convertible into common shares [2] - Following the milestone achievement, Blade Ranger received 685,004 warrants exercisable at an exercise price of $0.01 per share, with PainReform's shares trading at approximately $1.91, valuing the warrants at around $2 million [3] Group 2 - The CEO of Blade Ranger stated that the success of PainReform's software sales has improved the company's financial flexibility and supports accelerated business development [4] - The market value of the shares from the matured warrants is approximately NIS 4.5 million based on the current share price [4]

Core Insights - PainReform Ltd. has launched a strategic pilot program with Econergy Renewable Energy Ltd. to utilize its DeepSolar™ platform for optimizing operational efficiency and energy yield at a 92-megawatt photovoltaic plant in Romania [1][2][5] - The pilot aims to demonstrate the performance enhancements that DeepSolar™ can provide for large-scale renewable energy assets by analyzing real-time and historical data [2][6] - Successful completion of the pilot could lead to broader deployment of DeepSolar™ across Econergy's portfolio, potentially reaching a total capacity of 1 Gigawatt [3][6] Company Overview - PainReform Ltd. focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform [7] - The company aims to apply advanced technologies to improve clean energy operations and has a dual business model that includes both healthcare and sustainable energy sectors [7] Industry Context - Econergy Renewable Energy Ltd. is a leading independent power producer in Europe, with approximately 1 Gigawatt of photovoltaic capacity either operational or under construction [4] - The partnership reflects a shared vision for innovation and sustainability in the renewable energy sector, emphasizing the importance of advanced technologies in optimizing energy production [4][6]